The king of life science acquisitions has struck again. Thermo Fisher Scientific has announced plans to acquire Patheon, a Durham, North Carolina-based contract development and manufacturing organization with 9,000 employees worldwide.
Given Lucier's expertise in M&A, it'll be interesting to see how he expands NuVasive's product portfolio beyond this $380 million acquisition.
The future looks bright for the integrated specialty pharmacy model – for health systems, providers, and most importantly, for patients.
The biggest new healthcare product unveiled at CES this week was undoubtedly Life Technologies Corp.’s (NASDAQ:LIFE) new Ion Proton Sequencer, a bench-top machine that the company says will be able to sequence the entire human genome for $1,000 by the end of the year. (A side note: Illumina Inc. announced the release of a similar […]
Sometimes acquiring other drugmakers is the way to fill your company's development pipeline with new drugs. On Tuesday, Schering-Plough Corp. CEO Fred Hassan, a speaker at the Cleveland Clinic's ongoing Medical Innovation Summit, flew to Texas to launch Saphris, an anti-psychotic drug acquired in 2007.